tsukiko.kurokawa@metagentx.com We are pleased to announce that our Ulcerative Colitis drug development project has been selected by AMED, Japan Agency for Medical Research and Development, for the “FY2024 Strengthening Program for Pharmaceutical Startup Ecosystem : 4th Call for Proposal from Pharmaceutical Startups”.
This program was inaugurated to solve the shortage of large scale development funds for pharmaceutical startup development and commercialization, especially those engaged in pre-clinical study,
Phase 1 clinical study, Phase 2 clinical study or exploratory clinical study.
The program mandates that they also receive funding from venture capital firms (VCs) that are registered with AMED; the selected VCs should have experience in specializing in drug development and providing hands-on business management and commercialization support.
AMED will actively support plans to commercialize in overseas market in addition to Japan to achieve sufficient sales and growth of the startup.
For more information, please visit the following website: